Shirin Elizabeth Khorsandi, Arthur William Raven Day, Miriam Cortes, Akash Deep, Anil Dhawan, Hector Vilca‐Melendez, Nigel Heaton – 27 December 2016 – The aim was to determine the factors associated with the use of delayed abdominal closure in pediatric liver transplantation (LT) and whether this affected outcome. From a prospectively maintained database, transplants performed in children (≤18 years) were identified (October 2010 to March 2015). Primary abdominal closure was defined as mass closure performed at time of transplant.

Wai‐Kay Seto, Thomas Sau‐Yan Chan, Yu‐Yan Hwang, Danny Ka‐Ho Wong, James Fung, Kevin Sze‐Hang Liu, Harinder Gill, Yuk‐Fai Lam, Eric H.Y. Lau, Ka‐Shing Cheung, Albert K.W. Lie, Ching‐Lung Lai, Yok‐Lam Kwong, Man‐Fung Yuen – 27 December 2016 – Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)–negative, antibody to hepatitis B core antigen (anti‐HBc)–positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not been prospectively studied.

Yameng Sun, Jialing Zhou, Lin Wang, Xiaoning Wu, Yongpeng Chen, Hongxin Piao, Lungen Lu, Wei Jiang, Youqing Xu, Bo Feng, Yuemin Nan, Wen Xie, Guofeng Chen, Huanwei Zheng, Hai Li, Huiguo Ding, Hui Liu, Fudong Lv, Chen Shao, Tailing Wang, Xiaojuan Ou, Bingqiong Wang, Shuyan Chen, Aileen Wee, Neil D. Theise, Hong You, Jidong Jia – 27 December 2016 – Liver fibrosis is the net result of dynamic changes between fibrogenesis and fibrolysis. Evidence has shown that antiviral therapy can reverse liver fibrosis or even early cirrhosis caused by hepatitis B virus.

Kris V. Kowdley, Vinay Sundaram, Christie Y. Jeon, Kamran Qureshi, Nyan L. Latt, Amandeep Sahota, Stephen Lott, Michael P. Curry, Naoky Tsai, Nathorn Chaiyakunapruk, Yoori Lee, Jorg Petersen, Peter Buggisch – 27 December 2016 – Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus–infected patients who are treatment‐naive, do not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL. The effectiveness of this regimen, however, has not been fully confirmed by real‐world experience.

Naoki Yoshida, Takeshi Takamoto, Takuya Hashimoto, Yoshikazu Maruyama, Hayato Abe, Kei Shimada, Tadatoshi Takayama, Masatoshi Makuuchi – 27 December 2016

Henry B. Randall, Tarek Alhamad, Mark A. Schnitzler, Zidong Zhang, Sophia Ford‐Glanton, David A. Axelrod, Dorry L. Segev, Bertram L. Kasiske, Gregory P. Hess, Hui Yuan, Rosemary Ouseph, Krista L. Lentine – 27 December 2016 – Implications of prescription opioid use for outcomes after liver transplantation (LT) have not been described. We integrated national transplant registry data with records from a large pharmaceutical claims clearinghouse (2008‐2014; n = 29,673).

Kyung‐Suk Suh, Hyo‐Sin Kim, Nam‐Joon Yi, Kwang‐Woong Lee, Suk Kyun Hong, Kyung Chul Yoon, Adianto Nugroho, Hyeyoung Kim – 27 December 2016

Jean‐François Dufour – 27 December 2016

Manuela Sabelli, Giuliana Montosi, Cinzia Garuti, Angela Caleffi, Stefania Oliveto, Stefano Biffo, Antonello Pietrangelo – 27 December 2016 – Ferroportin (FPN1) is the sole iron exporter in mammals, but its cell‐specific function and regulation are still elusive. This study examined FPN1 expression in human macrophages, the cells that are primarily responsible on a daily basis for plasma iron turnover and are central in the pathogenesis of ferroportin disease (FD), the disease attributed to lack‐of‐function FPN1 mutations.

Deirdre Kelly, Steffen Hartleif, Henkjan J. Verkade, Jeremy Rajanayagam, Patrick McKiernan, George Mazariegos, Stefan Hübscher – 27 December 2016